Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 1
1974 1
1975 1
1976 3
1977 5
1978 1
1979 5
1980 2
1981 6
1982 2
1983 9
1984 10
1985 7
1986 22
1987 21
1988 19
1989 18
1990 24
1991 19
1992 29
1993 35
1994 30
1995 26
1996 34
1997 48
1998 32
1999 55
2000 47
2001 55
2002 74
2003 58
2004 77
2005 77
2006 101
2007 103
2008 115
2009 142
2010 146
2011 146
2012 219
2013 252
2014 234
2015 224
2016 249
2017 290
2018 287
2019 334
2020 387
2021 496
2022 503
2023 60
Text availability
Article attribute
Article type
Publication date

Search Results

4,563 results
Results by year
Filters applied: . Clear all The following terms were ignored: %, %, %, %, % The following terms were not found in PubMed: 22Jongen, 20JC, 5BAuthor
Page 1
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Reck M, et al. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31195357 Free article. Clinical Trial.
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) …
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI …
The EQ-5D and the EuroQol Group.
Lloyd A, Pickard AS. Lloyd A, et al. Value Health. 2019 Jan;22(1):21-22. doi: 10.1016/j.jval.2018.12.002. Value Health. 2019. PMID: 30661629 Free article. No abstract available.
Rhenium-Imido Corroles.
Alemayehu AB, Teat SJ, Borisov SM, Ghosh A. Alemayehu AB, et al. Inorg Chem. 2020 May 4;59(9):6382-6389. doi: 10.1021/acs.inorgchem.0c00477. Epub 2020 Apr 10. Inorg Chem. 2020. PMID: 32275406 Free PMC article.
Metallocorroles involving 5d transition metals are currently of interest as near-IR phosphors and as photosensitizers for oxygen sensing and photodynamic therapy. ...Against this backdrop, we describe rhenium-imido corroles, a new class of 5d metallocorroles, synthe …
Metallocorroles involving 5d transition metals are currently of interest as near-IR phosphors and as photosensitizers for oxygen sens …
Atlas Argentino de Calidad de Vida Relacionada con la Salud: Análisis de los datos de la Encuesta Nacional de Factores de Riesgo por Provincias.
Augustovski F, Rey-Ares L, Gibbons L. Augustovski F, et al. Value Health Reg Issues. 2013 Dec;2(3):398-404. doi: 10.1016/j.vhri.2013.10.006. Epub 2013 Dec 12. Value Health Reg Issues. 2013. PMID: 29702777 Spanish.
RESULTS: The survey included 41.392 subjects; the expanded population represented 96% of the adult population of Argentina. 8.82% of the population reported excellent health, 24.6% very good, 43.9% good and 22.3% regular or bad. 42.8% reported limitations in at least one o …
RESULTS: The survey included 41.392 subjects; the expanded population represented 96% of the adult population of Argentina. 8.82% of the pop …
Low dose naloxone for pruritus in systemic sclerosis: Case series and literature review.
Meridor K, Berookhim J, Levy Y. Meridor K, et al. Medicine (Baltimore). 2022 Jan 28;101(4):e28653. doi: 10.1097/MD.0000000000028653. Medicine (Baltimore). 2022. PMID: 35089206 Free PMC article. Review.
PATIENT CONCERNS AND DIAGNOSIS: We describe 4 female patients with systemic sclerosis suffering from severe pruritus, with an average 5D-itch score of 22.75. INTERVENTION AND OUTCOMES: Low-dose oral naloxone was initiated, followed by a significant improvement in th …
PATIENT CONCERNS AND DIAGNOSIS: We describe 4 female patients with systemic sclerosis suffering from severe pruritus, with an average 5D …
Temporal properties of positive and negative defocus on emmetropization.
Zhu X, Kang P, Troilo D, Benavente-Perez A. Zhu X, et al. Sci Rep. 2022 Mar 4;12(1):3582. doi: 10.1038/s41598-022-07621-6. Sci Rep. 2022. PMID: 35246571 Free PMC article.
A total of forty-six marmosets were treated monocularly with soft contact lenses for 4 weeks from 10 weeks of age (OD: + 5D or - 5D; OS: plano). Two control groups wore + 5D (n = 5) or - 5D (n = 13) lenses continuously for 9 h/day. ...Interrupting defo …
A total of forty-six marmosets were treated monocularly with soft contact lenses for 4 weeks from 10 weeks of age (OD: + 5D or - 5 …
Patient satisfaction with cluneal nerve entrapment surgery.
Kim K, Kokubo R, Isu T, Morimoto D, Morita A. Kim K, et al. Acta Neurochir (Wien). 2022 Oct;164(10):2667-2671. doi: 10.1007/s00701-022-05344-1. Epub 2022 Aug 16. Acta Neurochir (Wien). 2022. PMID: 35972558
The numerical rating scale (NRS) for LBP, the Oswestry Disability Index (ODI) score, and the EuroQOL 5-dimension, 5-level (EQ-5D-5L) scale before and 6 months after the operation were compared. Using these scores, the treatment outcome was compared with the patients' preop …
The numerical rating scale (NRS) for LBP, the Oswestry Disability Index (ODI) score, and the EuroQOL 5-dimension, 5-level (EQ-5D-5L) …
EQ-5D: a plea for accurate nomenclature.
Brooks R, Boye KS, Slaap B. Brooks R, et al. J Patient Rep Outcomes. 2020 Jul 3;4(1):52. doi: 10.1186/s41687-020-00222-9. J Patient Rep Outcomes. 2020. PMID: 32620995 Free PMC article.
Since 2009, EQ-5D has been available in three versions: EQ-5D-3L, EQ-5D-5L, and EQ-5D-Y, where 3L stands for three levels, 5L for five levels, and Y for youth. ...Two surveys - of arthritis applications, and 82 recent publications - found a variety of …
Since 2009, EQ-5D has been available in three versions: EQ-5D-3L, EQ-5D-5L, and EQ-5D-Y, where 3L stands for thr …
Comparison of the three-level and the five-level versions of the EQ-5D.
Christiansen ASJ, Møller MLS, Kronborg C, Haugan KJ, Køber L, Højberg S, Brandes A, Graff C, Diederichsen SZ, Nielsen JB, Krieger D, Holst AG, Svendsen JH. Christiansen ASJ, et al. Eur J Health Econ. 2021 Jun;22(4):621-628. doi: 10.1007/s10198-021-01279-z. Epub 2021 Mar 18. Eur J Health Econ. 2021. PMID: 33733344
A total of 1002 persons diagnosed with hypertension, diabetes, heart failure, and/or previous stroke completed both the EQ-5D-3L and the EQ-5D-5L questionnaires. The overall ceiling effect decreased from 46% with the EQ-5D-3L to 30% with the EQ-5D-5L a …
A total of 1002 persons diagnosed with hypertension, diabetes, heart failure, and/or previous stroke completed both the EQ-5D-3L and …
Health utility reporting in chronic rhinosinusitis patients.
Bewick J, Morris S, Hopkins C, Erskine S, Philpott CM. Bewick J, et al. Clin Otolaryngol. 2018 Feb;43(1):90-95. doi: 10.1111/coa.12903. Epub 2017 Jun 13. Clin Otolaryngol. 2018. PMID: 28498517
We plotted EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores separately against SNOT-22 scores and quantified associations using bivariate ordinary least squares regression analysis. ...Mean index score computed form the EQ-5D-5L was 0.75. Worse (h …
We plotted EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores separately against SNOT-22 scores and quantified assoc …
4,563 results